Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
EPO is available as a supplement or topical product
Clinical Context: The Phase 2 trial by Metabolic Pharmaceuticals found significant fat loss at 1mg (1,000mcg)/day over 12 weeks compared to placebo
Educational Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment
On the other hand, BPC-157 is the synthetic version of the naturally occurring Body Protection Compound in the gastric juice of organisms
While on the diet, the time needed for cholesterol crystals to form decreased in the placebo and ursodeoxycholic acid groups, but not in the omega-3 group, suggesting fish oil may prevent the increase in gallstone risk seen with low-calorie weight loss dieting (Mendez-Sanchez 2001)